UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12B-25

                           NOTIFICATION OF LATE FILING

                                                     SEC File Number: 0-20127

                                                     CUSIP Number: 296074-30-5



(Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form
10-D [ ] Form N-SAR [ ] Form N-CSR

      For the Period Ended: June 30, 2005
      [ ] Transition Report on Form 10-K
      [ ] Transition Report on Form 20-F
      [ ] Transition Report on Form 11-K
      [ ] Transition Report on Form 10-Q
      [ ] Transition Report on Form N-SAR

      For the Transition Period Ended: ________________________________


  Read Instruction (on back page) Before Preparing Form. Please Print or Type.
    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
                   VERIFIED ANY INFORMATION CONTAINED HEREIN.


If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:

- --------------------------------------------------------------------------------

- --------------------------------------------------------------------------------

PART I -- REGISTRANT INFORMATION

 Escalon Medical Corp.
- --------------------------------------------------------------------------------
(Full Name of Registrant)

- --------------------------------------------------------------------------------
(Former Name, if Applicable)

 565 East Swedesford Road, Suite 200
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)

 Wayne, PA  19087
- --------------------------------------------------------------------------------
City, State and Zip Code

PART II -- RULES 12B-25(B) AND (C)

If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate): [X]

      (a)   The reasons described in reasonable detail in Part III of this form
            could not be eliminated without unreasonable effort or expense;

      (b)   The subject annual report, semi-annual report, transition report on
            Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
            portion thereof, will be filed on or before the fifteenth calendar
            day



\
            following the prescribed due date; or the subject quarterly report
            or transition report on Form 10-Q or subject distribution report on
            From 10-D, or portion thereof, will be filed on or before the fifth
            calendar day following the prescribed due date; and

      (c)   The accountant's statement or other exhibit required by Rule
            12b-25(c) has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR,
N-CSR or the transition report or portion thereof, could not be filed within the
prescribed time period.

The Registrant's Annual Report on Form 10-K for the year ended June 30, 2005
could not be filed by the filing date without unreasonable effort and expense
because the Registrant needs additional time to provide information on
Registrant's acquisition of Drew Scientific Plc to the Registrant's auditors to
complete their audit. The Registrant expects to file its Form 10-K no later than
the extended due date.

PART IV -- OTHER INFORMATION

(1)   Name and telephone number of person to contact in regard to this
      notification

       Richard J. DePiano             (610)                       688-6830
      -------------------------     ---------                -------------------
                  (Name)           (Area Code)               (Telephone Number)

(2)   Have all other periodic reports required under Section 13 or 15(d) of the
      Securities Exchange Act of 1934 or Section 30 of the Investment Company
      Act of 1940 during the preceding 12 months or for such shorter period that
      the registrant was required to file such report(s) been filed? If answer
      is no, identify report(s).

      Yes [X]     No [ ]

(3)   Is it anticipated that any significant change in results of operations
      from the corresponding period for the last fiscal year will be reflected
      by the earnings statements to be included in the subject report or portion
      thereof ? Yes [X] No [ ]

If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

Escalon Medical Corp.  has caused this notification to be signed on its
behalf by the undersigned hereunto duly authorized.

Date:  September 29, 2005

                                  By:/s/ Richard J. DePiano
                                     -------------------------------------------
                                        Richard J. DePiano
                                         Chairman and Chief Executive Officer



      INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and title of
the person signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.


                                   -2-



                     EXPLANATION OF THE ANTICIPATED CHANGE

Registrant anticipates a change in results of operations from the corresponding
period for the last fiscal year due to the previously reported acquisition of
Drew in 2004. For further information, we incorporate by reference the
Registrant's Form 8-K dated September 29, 2005.

                                   -3-